CHICAGO, Feb. 9 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, is providing a preview of its priorities and anticipated milestones for 2010 based on a foundation of progress and strengthened strategic focus achieved in 2009.
"We believe that 2010 has the potential to be a pivotal year for Advanced Life Sciences, as we advance Restanza™ toward registration on two major fronts, in community acquired bacterial pneumonia (CABP) and as a broad spectrum countermeasure for biodefense, as we move toward expanding the Restanza franchise with new formulations and new indications and as we aggressively pursue opportunities to strengthen our business," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "We are excited about our prospects in 2010. We have sharpened our focus on key business strategies and priorities, fortified our commitment to meet the increasingly urgent market need for breakthrough antibiotics and renewed our confidence in the therapeutic and commercial potential of our Restanza pipeline."
Added Dr. Flavin: "The year 2009 was filled with both accomplishments and challenges. We are proud of our company's resiliency and resolve to reach our goals and advance Restanza toward the market. Ours is a focused and unified team with a strong personal and professional commitment to enhancing public health with novel antibio
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved